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Abstract
Renal Cell Carcinoma (RCC) is typically asymptomatic and surgery usually increases patient’s lifespan only for early stage
tumours. Moreover, solid renal masses cannot be confidently differentiated from RCC. Therefore, markers to distinguish
malignant kidney tumours and for their detection are needed. Two different peptide signatures were obtained by a MALDI-
TOF profiling approach based on urine pre-purification by C8 magnetic beads. One cluster of 12 signals could differentiate
malignant tumours (n = 137) from benign renal masses and controls (n = 153) with sensitivity of 76% and specificity of 87%
in the validation set. A second cluster of 12 signals distinguished clear cell RCC (n = 118) from controls (n = 137) with
sensitivity and specificity values of 84% and 91%, respectively. Most of the peptide signals used in the two models were
observed at higher abundance in patient urines and could be identified as fragments of proteins involved in tumour
pathogenesis and progression. Among them: the Meprin 1a with a pro-angiogenic activity, the Probable G-protein coupled
receptor 162, belonging to the GPCRs family and known to be associated with several key functions in cancer, the
Osteopontin that strongly correlates to tumour stages and invasiveness, the Phosphorylase b kinase regulatory subunit
alpha and the SeCreted and TransMembrane protein 1.
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Introduction
Biomarkers able to characterize and predict multifactorial
diseases, such as cancer, are still one of the most important targets
for all the ‘‘omics’’ investigations.
These clinically oriented studies have also been successfully
performed in the peripheral fluids, taking advantage of non- or
very low-invasive collection methods. In particular, the urinary
low-molecular-weight proteome, also termed urinary peptidome
[1,2], represents an important source of information for biomarker
discovery.
The analysis of the urinary peptidome should be most
applicable to renal diseases, given that urine should contain a
higher amount of molecules, including these naturally occurring
polypeptides, with an altered concentration deriving directly from
kidney. In particular, Renal cell carcinoma (RCC) needs markers
for detection, prognosis and therapeutic targeting [3]. Whereas
RCC includes an heterogeneous group of tumours with variable
clinical outcomes, that range from indolent to explicitly malignant
[4], the most common histological type is represented by clear cell
RCC (ccRCC), and comprises approximately 60% of all renal
tumours [5].
RCC is the third most frequent malignancy of the genitourinary
tract accounting for about 90% of all renal malignancies and the
most fatal urological cancer, causing approximately 2% of all
cancer deaths [6]. It is noteworthy that this carcinoma is one of the
human cancers with an increasing incidence. Currently, as RCC is
typically asymptomatic, most cases are frequently detected as an
incidental renal mass, imaging the abdomen for other reasons such
as during the work-up of acute renal failure [5]. About 30% of
RCC patients will present metastases at the time of the diagnosis,
many others will develop metastasis after surgical resection and for
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these patients the prognosis is dismal. Indeed, treatment of
metastatic RCC remains highly challenging since its progression-
free survival is very poor among these patients [3]. Traditionally
RCC is known to be refractory to chemotherapy and to
radiotherapy. Surgical removal of the tumour is considered the
only effective treatment and, where feasible, may result in
remission in up to 40–60% of cases [7].
Management of RCC is benefiting from the increasing role of
small tumour masses detection, greater understanding of the
metabolic pathways involved, new targeted medical treatments for
metastatic RCC, and evolving surgical and minimally invasive
image-guided treatment techniques [8]. Although in the absence
of biomarkers, renal imaging is most often recommended by
advocates of screening, a confident histological classification and
diagnosis with this technique is not always feasible, especially for
some ambiguous cystic and solid renal lesions [9]. Therefore, early
diagnosis could highly improve survival rates for patients with
renal cancer and also for those with localized tumours. Moreover,
welfare will benefit from a test able to distinguish small kidney
malignant masses from benign lesions driving the patient to low or
high intense follow-up.
The present work is focused on the application of a single-step
purification using C8 functionalized magnetic beads (C8-MB)
followed by MALDI-TOF analysis and nLC-ESI-MS/MS to
explore possible urinary peptide signatures of patients affected by
ccRCC, by other kidney tumours and control subjects.
Materials and Methods
Chemicals and standards
Profiling Kit 1000 C8-MB, a-cyano-4-hydroxycinnamic acid
(CHCA), Protein Calibration Standard I (ProtMix I) and Peptide
Calibration Standard II (PepMix II) were supplied by Bruker
Daltonics GmbH (Bremen, Germany).
Urine collection and handling procedure
Urine samples were collected from patients the day before
surgery and from healthy volunteers at ‘‘Ospedale Maggiore
Policlinico’’ Foundation (Milan, Italy), San Gerardo Hospital
(Monza, Italy) and Desio Hospital (Desio, Italy). All subjects had
signed an informed consent prior to sample donation. Study
protocols and procedures were approved by the local ethic
committee (U.O. Comitato di Etica e Sperimentazione Farmaci
Direzione Scientifica Fondazione IRCCS Ca’Granda Ospedale
Maggiore Policlinico, Milano and Comitato Etico Azienda
Ospedaliera San Gerardo, Monza) and analysis were carried out
in agreement with the Declaration of Helsinki. Second morning
midstream urine was collected in sterile urine tubes (Anicrin s.r.l.,
Italy) [10].
As concerning the MB protocol, the binding, washing and
desorption steps of the beads were based on the manufacturer
instructions and slightly modified, as previously reported (see
supplemental material S1) [11]. In particular, 40 mL of urine of
each subject was used both for MALDI-TOF profiling and the
preparation of two urine pools (n = 80 each) used for peptide
identification. The two pools from ccRCC patients or control
subjects urine were manually purified with magnetic beads.
MALDI-TOF peptide profiling
Fractionated samples were analysed in linear mode (MALDI-
LM) and reflector mode (MALDI-RM) using an UltrafleXtre-
meTM MALDI-TOF/TOF instrument (Bruker Daltonics, Ger-
many) as previously described and reported in supplemental
materials S1 [11]. Spectra processing was based on baseline
subtraction and realignment using a subset of seven frequent
common peaks (at m/z-values 1162, 1511, 1681, 1895, 1912,
2236, and 3373) for liner mode with a peak tolerance of
1000 ppm. An internal calibration was also performed on reflector
data using four peaks (at m/z-values 1680.93, 1912.06, 2040.17
and 2659.32) with a tolerance in peak assignment of 100 ppm
except for the last one that was 200 ppm.
ClinProToolsTM software v. 2.2 (Bruker Daltonics, Germany)
was used for multiple spectra comparison after their normaliza-
tion. Data selection was performed with: resolution value of 800,
‘‘Convex Hull’’ baseline correction with a baseline flatness of 0.80,
null or not recalibratable spectra exclusion. The mean spectrum
obtained from each subject data set was used for the statistical
elaboration.
List of peaks (m/z) with their area (as a measure of compound
abundance) was obtained with a S/N threshold of 3 and peak
areas were calculated using zero level integration type on the total
average spectrum for the statistical analysis.
Mean area values, before and after spectra processing, of all
clusters signals for each sample groups are reported in Table S1.
Peptide identification by MALDI-TOF/TOF
For peptide identification, LIFT-TOF/TOF spectra were
acquired using the UltrafleXtremeTM MALDI-TOF/TOF mass
spectrometer without additional collision gas. Analyses were
performed using appropriate acquisition settings as previously
reported [11]. MS/MS data were processed using FlexAnalysisTM
software v. 3.3 (Bruker Daltonics, Germany). Database searching
was performed by an in-house Mascot search engine (Version:
2.4.1) with the same parameters already described [11].
Expression profile analysis and statistical analysis
Statistical analysis was conducted following the sequence of
processes as reported in Figure S1 and specified in its caption.
Briefly, to apply the correct statistical procedure we first evaluated
the assumption of normality and the homogeneity of variance,
then appropriate parametric or non-parametric tests were used for
case/control comparisons and correlations. Discriminant models
were built using Rapid Miner (RaM) [12–14] workflow based on
SVM algorithm (Figure S2 and its caption). The performances of
our inference process are given through indices which are broadly
applied to measure the classification performance of an inference
system; i.e., sensitivity, specificity, positive (PPV) and negative
predictive values (NPV) [15]. The receiver operating characteristic
curve analysis (ROC) and area under the curve (AUC) were also
evaluated as previously described [16].
Peptide identification by nLC-ESI-MS/MS
Endogenous peptides in the enriched fractions obtained by MB
purification of urine pools from controls (n = 80) and ccRCC
patients (n = 80) were identified by nLC-ESI-MS/MS. Briefly,
purified samples were desalted using ZiptipTM m-C18 Pipette Tips
(Millipore Corp, Bedford, MA) as already reported [11]. Desalted
fractions were injected into Dionex UltiMate 3000 rapid
separation (RS) LC nano system (Thermo Scientific, Germany)
coupled online with an Impact HDTM mass spectrometer (Bruker
Daltonics, Germany).
Peptides were first loaded onto a m-precolumn (Dionex, Acclaim
PepMap 100 C18, cartridge, 300 mm i.d.65 mm, 5 mm), followed
by separation on the analytical 50cm nano column (Dionex,
0.075 mm ID, Acclaim PepMap100, C18, 2 mm). Multistep
360 min gradients with a ramp from 4 to 35% in 245 min of
mobile phase B (0.1% FA/80% CHCN) were used. The mass
Urinary Peptidome of RCC
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spectrometer was operated in the data-dependent-acquisition
mode.
Raw MS/MS data were lock-mass corrected, deconvoluted and
converted to XML peak lists and processed using an in-house
Mascot search engine (v2.4.1). Peptide identification details are
provided in Supplemental Materials S1. Briefly, database search-
ing was restricted to human Swiss-Prot (accessed Apr 2014,
544,996 sequences; 193,815,432 residues). No enzyme and any
fixed modification was set in search parameters. Mass tolerances
for all identifications were generally fixed at 20–5 ppm MS and
0.5–0.05 Da MS/MS. Acetyl (N-term) was set as variable
modification in Mascot search parameters. Mascot thresholds
score for homology and identity and decoy database were used as
peptide level filters of peptide significance (False Discovery Rate ,
1%).
Results
Clinical data and study design
Urine collected from 137 healthy subjects (Ctrls) (81 men, 56
women), 118 clear cell RCC (ccRCC) (73 men, 45 women), 35
other different histological subtypes (non-ccRCC), (22 men, 13
women) (16 benign renal masses and 19 malignant non-ccRCC)
patients were used in the present study. Fisher test did not reveal
any gender dependence in the studied cohort. Mean age for
controls was 48.7 with a range of 24–79 years, while 64.53 for
patients with a range of 33–88 years. Patients were classified
according to the 2009 TNM (tumour-node-metastasis) system
classification and their clinical characteristics are described in
Table 1 [17]. Histological analysis was performed on patients
based upon the Fuhrman grading system, sarcomatoid and cystic
differentiation, tumour necrosis, microvascularity and urinary
infiltration. Tumour patients underwent surgical excision of the
renal lesion.
Protein profiles and cluster analysis
Aiming to perform a profiling analysis of the urinary peptidome
and build statistical patterns of potential discriminant biomarkers,
group comparisons were evaluated.
About 202 peaks common to the three groups have been
detected in MALDI-TOF averaged peptide profiles of controls,
ccRCC and non-ccRCC patients after C8-MB sample pre-
purification. Ion signals correlating with the age (Spearman test)
were not considered in the subsequent elaborations [18].
Discriminant pattern recognition was performed using SVM
algorithm supplied by RaM software. Initially, the entire cohort of
patients was divided into malignant tumours (n = 137) and benign
renal masses plus healthy subjects (n = 153) and a discriminant
cluster of twelve peptides (linear mode m/z-values 1116, 1670,
2216, 2528, 2661, 3162, 3443, 5032, 5532, 6130, 6786 and 10654)
was built with 78% and 88% of specificity and sensitivity,
respectively, (Table 2A).
Based on the recommendations for biomarker discovery and
qualification in clinical proteomics [19], the model was subse-
quently evaluated in an independent set of 61 (benign and
controls) and 55 (malignancies) subjects (Table 2B). The cluster
of 12 signals allowed us to discriminate the benign/controls from
malignant tumours with 87% and 76% of specificity and sensitivity
respectively, and an AUC of 0.89 (Figure S3), confirming its high
diagnostic accuracy according to the criteria suggested by Swets
[20]. Peaks selected by SVM to build the discriminant clusters
have not necessarily to be statistically different in the group
comparisons. They are selected through a forward selection
scheme with SVM as inference procedures which, in turn, follows
a different way to select discriminative features. Statistical analysis
showed that eight of these peaks (at m/z-values 1116, 1670, 2216,
2528, 2661, 3162, 3443 and 5532) had a higher urinary
concentration (p,0.05) while three (at m/z-values 5032, 6130
and 6786) had a lower urinary abundance (p,0.05) in malignant
kidney tumour patients compared to controls and subjects with
benign renal masses (Table 3 and Figure S4).
In addition, using an interactive analysis, a different case/
control classification task was also performed for Ctrls versus
ccRCC. Classification performances in training and validation test
are reported in Table 4. All controls and ccRCC patients were
used for feature selection and cross-validation procedures and a
cluster of twelve peptides (linear mode m/z-values 1670, 1727,
2192, 3005, 3252, 3636, 4623, 5432, 5532, 5964, 6062 and 6175)
was selected by a statistical analysis of MALDI-TOF spectra.
Performance of the model resulted in a specificity of 90% and in a
sensitivity of 82% (Table 4A). This good diagnostic capability was
proved by a validation on the second independent set of data (53
Ctrls and 49 ccRCC patients), confirming the specificity of 91%
and a sensitivity of 84% (Table 4B). Four ions (at m/z-values
4623, 5432, 6062 and 6175) were observed to be in lower
concentration (p,0.05) in ccRCC patients, and other four (at m/z-
values 1670, 1727, 3636 and 5532) showed an increased
abundance (p,0.05) (Table 5 and Figure S5). The AUC of
the model was 0.96 (Figure S6), pointing towards an accurate test
[20].
Endogenous peptide identification
The identification of urinary endogenous peptides correspond-
ing to signals included in the two discriminative models was
obtained by nLC-ESI-MS/MS analysis of C8-MB enriched
fractions (two pools of 80 controls and 80 patients). Alignment of
the m/z-values determined by MALDI-LM with those from LC-
ESI was based on the mass spectra acquired by MALDI-RM of
the C8-MB fractions. The mass measurement errors (MMEs) of
assigned peptides measured by MALDI-RM and by MALDI-LM
varied from 253 to 72 ppm and 2297 to 77 ppm, respectively.
The differences between mass measurements in ESI and MALDI-
RM mode varied from 279 to 50 ppm. Seven MALDI-LM
signals were assigned to eight different protein fragments
(Table 6).
The identity of the peptide giving rise to the MALDI-LM signal
at m/z 2192, included in the model, could not be unambiguously
obtained (Table 6). The specific contributes to the MALDI-LM
peak of the two peptides at m/z 2190.765 (GP162) and at m/z
2190.778 (KPB1), identified by LC-ESI, were prevented from
being distinguished due to the low molecular mass differences
between the two amino acid sequences coupled with the resolution
power of MALDI-RM (Table 6).
The identity of one signal present in MALDI-LM spectra
corresponding to m/z-value 2661, assigned to a fragment of FIBA,
was further confirmed by MALDI-TOF/TOF (Mascot score
exceeding the significant threshold of identity, score = 166, p,
0.05).
Discussion
To date, thousands of different proteins/peptides have been
sequenced in human urine, providing a greater insight into the
urinary content and suggesting more exhaustive disease-specific
researches for their potential use in clinical practice. Biomarker
discovery studies are widely performed on urine samples, with the
aim of developing a non-invasive diagnostic tool for prostate
Urinary Peptidome of RCC
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cancer [21], diabetic nephropathy [22], chronic kidney disease
[23] as well as for RCC [3,10,24].
Thus far, many studies performed using Western blot analysis
have reported several proteins with an altered urinary concentra-
tion in RCC patients, relative to control subjects, with potential
diagnostic/prognostic capabilities. An over-concentration of the
urinary nuclear matrix protein 22 was found in 23 of 35 RCC
patients compared to 30 patients with kidney stone and renal cystis
used as controls [25]. The urinary 14-3-3 protein alpha/beta has
also been shown to be in a higher concentration in RCC patient
urine compared to that from healthy volunteers samples [26]. The
diagnostic capability of this protein resulted in an AUC of 0.88.
Two other proteins, Aquaporin-1 and Peirilin-2, were observed to
be at higher levels in the urine of 63 RCC patients versus 43
healthy subjects [27]. The sensitivity and specificity values were in
the range of 90–100% for both these proteins. The urinary
concentration of these proteins returned to levels similar to those
found in controls 2–4 weeks after surgery. KIM-1, a biomarker for
the detection of proximal tubules epithelial cells after ischemic or
toxic injury in humans, has also been shown to be increased in the
urine of RCC patients [28]. However, none of these results have
been validated in an independent cohort of patients.
Highly sensitive profiling studies require a combination of MS
and separation technologies based on different types of chroma-
tography. Recently, Frantzi et al. have described a model of 86
signals detected in the urine of healthy subjects and RCC patients
by CE-MS with a sensitivity and specificity of 80% and 87%,
respectively [29]. They could identify 40 of these markers and
Table 1. Patients clinical characteristics according to the 2009 TNM (tumour-node metastasis) system classification.
N6 of PATIENTS
ALL 153
Mean 6 SD age at diagnosis 64.53610.97
Median age at diagnosis (range) 33–88
GENDER
Males 95
Females 58
STAGING
Primary Tumor (T)
pT1 91
pT2 26
pT3 12
pT4 0
unknown 8
Regional lymph nodes (N)
NX 77
N0 40
N1 1
unknown 19
GRADE
G1 7
G2 86
G3 24
G4 3
unknown 17
HISTOLOGY
Clear cell RCC 118
Papillary RCC 9
Chromophobe 5
Oncocytoma* 8
Angiomyolipoma* 5
Other subtypes** 8
TUMOR TYPE
Malignant 137
Benign 16
* = benign renal masses
** = 5 malignant subtypes and 3 benign renal masses
doi:10.1371/journal.pone.0106684.t001
Urinary Peptidome of RCC
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most of them were fragments of collagen, fibrinogen and Na/k-
transporting ATPase. The authors suggest that these markers are
the consequence of different proteases specific to RCC, of changes
in proteolytic activity in the microenvironment of the kidney
tumours, and of kidney damage.
Successful discoveries of peptide signatures through MALDI
MS profiling have been reported for various human diseases
comprising of kidney pathologies [10]. In these studies urine
samples were pre-fractionated before MS-analysis through differ-
ent approaches [30] or beads [31–34].
Aiming to detect clusters of ions with diagnostic capability in
RCC, urinary protein profiles were investigated by several groups
using SELDI technology. Rogers et al. were able to build a neural-
network model with a sensitivity and a specificity of 98.3–100%.
These performances declined to 41–77% when tested in an
independent set of samples [30]. Later, Wu et al. also built a
cluster with four differentially represented peptides showing a
sensitivity and specificity of 80%–89.6% in the training phase, that
decreased to 67.8–81.5% in the validation phase [35]. However,
none of these groups were able to provide the identity of their
markers. Recently Alves et al. [36] could cluster RCC patients and
controls using a SELDI-TOF approach. They were also able to
provide the identity of several protein signals by SDS-PAGE
followed by LC-ESI but no information about the diagnostic
capability of the outcomes was given. We have previously reported
in a pilot study the possibility to discriminate kidney tumours (34
clear cell RCC, 4 papillary RCC and 1 mixed RCC+papillary)
from controls based on urinary signature [10]. However, due to
the low and not homogenous groups of patients and controls,
results have to be confirmed on a wider and more appropriate
dataset. Moreover, the possibility to differentiate malignant from
benign renal masses has not be considered.
Therefore, in this study we have investigated the urinary low
molecular weight proteome in a larger cohort of healthy volunteers
(n = 137), ccRCC (n= 118), and of 35 non-ccRCC patients using a
pre-purification procedure based on C8 functionalized magnetic
beads in combination with MALDI-TOF analysis. About sixty
percent of the enrolled patients and controls were used in the
training phase of the SVM and the remaining subjects for the
independent test evaluation of the models. Patterns of urinary
Table 2. Performances of the cluster of twelve signals to discriminate malignant tumours from benign renal masses or controls
(False = Benign or controls; True = Malignant) with k-fold = 10 cross-validation (A) and of the model, originated in the training
phase using about 60% of the data, in validation test using the other about 40% of the studied subjects (B).
A true False true True class precision
pred. False 120 17 87.6%a
pred. True 33 120 78.4%b
Spec., Sens. 78.40% 87.60%
B true False true True class precision
pred. False 53 13 80.3%a
pred. True 8 42 84.0%b
Spec., Sens. 86.90% 76.40%
Spec. = Specificity; Sens. = Sensitivity; pred. = Prediction; Class precision: a = Negative Predictive Value and b= Positive Predictive Value; Precision = Relative number
of correctly classified examples among all examples classified as positive i.e. precision = (Positives Correctly Classified)/(Total Predicted Positives). Note that the Total
Predicted Positives is the sum of True Positives and False Positives. This is the same for the Negative Predictive Value. True True = True positive; true False = True
negative
doi:10.1371/journal.pone.0106684.t002
Table 3. Urinary relative concentration (malignant/benign+ctrl) and p-value of the twelve ions included in the model able to
distinguish benign renal masses or controls from malignant kidney tumours.
Ions (m/z) p-value Urinary concentration
1116 ,0.001 Up
1670 ,0.001 Up
2216 ,0.05 Up
2528 ,0.001 Up
2661 ,0.001 Up
3162 ,0.001 Up
3443 ,0.001 Up
5032 ,0.001 Down
5532 ,0.05 Up
6130 ,0.001 Down
6786 ,0.001 Down
10654 . 0.05 n.s.
n.s. = not statistically different.
doi:10.1371/journal.pone.0106684.t003
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peptide markers able to distinguish RCC from controls and to
significantly differentiate kidney cancer from benign lesions were
searched.
In biomarker discovery and classification field, the size of the
model is a crucial aspect [37]. The model should be built avoiding
over-fitting but preserving generalization, in terms of capability to
correctly classify new subjects. In this study we limited the clusters
to no more than 20 features [37].
Initially we focused on the possibility to distinguish benign renal
masses or healthy subjects from malignant tumours and a classifier
with twelve urinary peptides with an AUC of 0.89 was generated.
Then, we afforded the possibility to discriminate ccRCC patients
from healthy subjects and a classifier with twelve peptides was
selected with good discriminating capability that were confirmed
in an independent cohort of subjects with an AUC of 0.96.
Identity of seven of the ions included in the clusters were obtained
by MALDI-TOF/TOF and by nLC-ESI-MS/MS analysis. Most
of them were different from those identified by CE-MS and used
in the model by Frantzi et al. [29] and, interestingly, most of them
were correlated to the presence of a tumour mass. This is not
surprising since the data on urinary peptidome delivered from
different pre-fractionation of sample and from a different
chromatographic separation provide complementary information
[38].
Hereby we describe two patterns of twelve urinary peptides with
a high discrimination power obtained by an SVM-based statistical
approach. Seven of these signals were most likely identified.
In particular, two ions at m/z 1670 and 2216 observed in
MALDI-LM spectra were identified as fragments of the human
glycoprotein uromodulin (UMOD/THP) and they were present in
higher concentration in patients affected by both ccRCC and
other malignant kidney tumours. The urinary excretion of
UMOD has been studied in various physio-pathological states,
but its precise biological role is still undefined. Clinical relevance of
this protein has been described in several pathologies and THP
mutations have been associated with chronic kidney disease,
altered glomerular filtration rate and decreased urinary excretion
[39]. Furthermore, decreased UMOD expression has been
observed in end-stage renal disease, in kidney neoplasms [40,41]
and in cysts from autosomal dominant polycystic kidney disease
Table 4. Performances of the cluster of twelve signals to discriminate ccRCC patients from controls (False = Controls; True =
ccRCC) with k-fold = 10 cross-validation (A) and of the model, originated in the training phase using about 60% of the data, in
validation test using the other about 40% of the studied subjects (B).
A true False true True class precision
pred. False 123 21 85.42%a
pred. True 14 97 87.39%b
Spec., Sens. 89.78% 82.20%
B true false true true class precision
pred. false 48 8 85.71%a
pred. true 5 41 89.13%b
Spec., Sens. 90.57% 83.67%
Spec. = Specificity; Sens. = Sensitivity; pred. = Prediction; Class precision: a = Negative Predictive Value and b = Positive Predictive Value. Precision = Relative
number of correctly classified examples among all examples classified as positive i.e. precision = (Positives Correctly Classified)/(Total Predicted Positives). Note that the
Total Predicted Positives is the sum of True Positives and False Positives. This is the same as the Negative Predictive Value.
True True = True positive; true False = True negative.
doi:10.1371/journal.pone.0106684.t004
Table 5. Urinary relative concentration (ccRCC/ctrl) and p-value of the twelve ions included in the model able to distinguish
controls from ccRCC.
Ions (m/z) p-value Urinary concentration
1670 ,0.001 Up
1727 ,0.001 Up
2192 . 0.05 n.s.
3005 . 0.05 n.s.
3252 . 0.05 n.s.
3636 ,0.001 Up
4623 ,0.001 Down
5432 ,0.001 Down
5532 ,0.05 Up
5964 . 0.05 n.s.
6062 ,0.001 Down
6175 ,0.001 Down
n.s. = not statistically different.
doi:10.1371/journal.pone.0106684.t005
Urinary Peptidome of RCC
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[42]. Moreover it was also reported with a lower abundance in
other pathologies like renal calculi disease [43], IgA nephropathy
[44] or diabetic nephropathy [45]. The relative concentration of
two urinary UMOD fragments, at m/z 1912 and 1824, included in
a discriminant model able to distinguish RCC patients from
controls in our previous pilot study [10], was confirmed by our
findings (data not shown). In a peptidome profiling study on urine
samples from healthy subjects exposed to high altitude hypoxia
another UMOD peptide, Val592IDQSRVLNLGPITArg606, a few
amino acids shorter than fragments identified in this study, was
also detected as altered in urinary levels [34].
The ion at m/z 2659 was identified as a fragment of fibrinogen
alpha chain (FIBA) and was found highly represented in the urine
of patients with cancer compared to healthy subjects. This peptide
was also identified by Siwy J et al. [46] but not included in their
discriminative model for RCC [29].
However, particular significance could be ascribed to those
proteins, showing a strong correlation with tumour development
and progression. A fragment of MEP1A (m/z 1727), a zinc-
dependent metalloproteinases abundantly expressed in the apical
membranes of renal proximal tubules was observed as over
represented in ccRCC urine [47,48]. It has been recently reported
that MEP1A enzyme exhibits a broad expression pattern,
implicating functions in angiogenesis, cancer, inflammation and
fibrosis [49–52]. Interestingly, a relevant pro-angiogenic activity
has been described for this meprin [53,54] with a molecular
mechanism based on proteolytic activation of pro-angiogenic
growth factors, such as VEGF-A [55–57]. Moreover, meprin a is
reported to be expressed in several different tumours, as in breast
and colorectal carcinomas [58,59] and probably associated to the
transition to malignant stages of colorectal carcinoma [54].
However, its onco-expression is likely to be specific between
different cancers, e.g. with quite low levels in ovarian cancer
compared with gastrointestinal carcinomas [60]. Finally, there is
data indicating that meprins are involved in a complex with
hypoxia-inducible factor-1a (HIF-1a) proposing a possible partic-
ipation of these proteins in oxygen sensing mechanisms and in the
response of the kidney proximal tubule cells to hypoxia process
[61].
Two different amino acid sequences have been recognized to
give rise to the ccRCC discriminant signal observed at m/z 2192
in MALDI-LM spectra: a fragment of Probable G-protein coupled
receptor 162 (GP162) and a sequence derived from Phosphorylase
b kinase regulatory subunit alpha, skeletal muscle isoform (KPB1).
The first protein (GP162), is an orphan receptor assigned to G
protein coupled receptors (GPCRs) family involved in signal
transmission [62]. GPCRs are associated with several functions
largely correlated to cancer such as cell proliferation, angiogenesis,
tumour progression and development [63]. Many GPCRs are
over-expressed in various cancer types and they are constitutively
active in malignant cells causing an aberrant response to various
signals [63]. The protein Phosphorylase b kinase regulatory
subunit a is a key regulatory enzyme of glycogen metabolism [64].
Glycogen can be broken down rapidly when glucose is needed,
and Phosphorylase b kinase switches on another enzyme called
glycogen phosphorylase b by converting it into the more active
form, glycogen phosphorylase a. Alteration of KPB1 seems to be
associated with muscle phosphorylase b kinase (PHK) deficiency, a
rare disorder caused by mutations in the gene coding for this
protein [65]. To our knowledge, whereas this protein certainly
plays an important role in providing energy for cells, there is no
evidence in literature that may explain a possible association with
cancer.
A fragment of OSTP (m/z 2528) was found in higher
concentration in urine of malignant tumour patients. Several
studies have shown its abundance both in tumour and tumour
microenvironment cells [66]. In particular, a significant cytoplas-
mic staining has been reported for a variety of cancer tissues,
including renal carcinomas, while a low staining has been shown
for breast and skin cancers [67]. It was proposed a correlation
between tissue and plasma/serum levels of Osteopontin and
prognosis in a huge number of cancers. In particular, Coppola et
al. have suggested a possible role of Osteopontin in tumour
progression as they found a high expression of OSTP in 72% of
tissue samples of RCC patients analysed by immunohistochemistry
and these results correlated with tumour stage [67]. In addition,
Ramankulov et al. analysed plasma of RCC patients at different
stages and metastatic grades by an enzyme immunometric assay
and they described high levels of this protein in plasma of patients
with RCC with regional lymph nodes and its expression reached
the highest values in patients with distant metastases [68]. Ye et al.
analysed urine samples of postmenopausal women with ovarian
cancer and benign conditions and from nonsurgical controls by
SELDI-TOF MS and two-dimensional gel electrophoresis and
they identified some fragments of Osteopontin strongly correlated
to tumour stages and invasiveness, suggesting their use as urine
biomarkers, in particular for patient prognosis and tumour
metastatic power [69]. Furthermore, the high expression of
Osteopontin and CD44 in tissue samples of ccRCC seems to
correlate with poor prognosis [70].
A fragment of the extracellular domain of SeCreted and
TransMembrane protein 1 (SCTM1) (m/z 1116) was at a higher
intensity in the urine of patients affected by kidney malignant
tumours. The SECTM1 protein level was observed to be increased
in many tumours, including breast cancer, leukemia cell lines and
melanoma [71]. Kuk et al. have included SCTM1 among a panel
of 52 possible candidate biomarkers for ovarian cancer [72].
In conclusion, the discriminant models described in this study
might be useful in distinguishing renal masses which can’t be
confidently defined using radiology alone and, as it stands, still
need a confirmatory biopsy. In compromised patients, kidney
biopsies can be technically challenging and hazardous. These
patients would benefit from our findings, avoiding this invasive
procedure in order to attain a correct diagnosis. Moreover, the
urinary proteomic signals typical of kidney cancer could also be
extremely useful for the evaluation of the vitality of cancer cells,
during and after target therapies, to estimate the response to the
treatment. Urine markers could also help to detect initial relapses
in partially resected kidneys that are often very hard to diagnose as
current imaging techniques are unable to easily distinguish
between a surgical modification of the parenchyma, due to a
inhomogeneous scar, or an initial disease recurrence. Further-
more, urinary markers could easily assess the residual vitality of the
tumour after minimally invasive techniques, such as ablation with
percutaneous radio-frequency, cryotherapy, microwave and high-
intensity focused US (HIFU), which are suggested as treatments in
selected patients with a genetic predisposition to multiple tumours,
with a solitary kidney, with bilateral tumours or elderly patients.
Since further research is needed in order to determine the
oncological success rate of these procedures and due to the efforts
related to the follow-up, urinary markers may be used to survey
these patients.
Supporting Information
Figure S1 Scheme of the statistical analysis using R and
RapidMiner. Differentially represented signals are detected
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(block 5) according to the standard assumptions for parametric
models (block 3). RapidMiner (RaM) was applied (block 6) for
forecasting a suitable predictive cluster of signals. The conceptual
sequence of operational steps applied in RaM is given in Figure
S2.
(TIF)
Figure S2 RapidMiner workflow. A: Data is retrieved by the
‘‘Input’’ operator and the feature selection is performed (‘‘Forward
Selection operator’’). B: Feature selection encapsulates a cross
validation process (‘‘Cross Validation operator’’) to select the most
performing set of features. C: Cross Validation operator
encapsulated a k-fold cross validation process. First a classifier is
built describing a predetermined set of data classes. Then, the
model (a trained SVM) is used for testing new classification
examples. The first inner operator (‘‘SVM’’) realizes the first step
(Training). The second inner operator (‘‘Apply Model’’) realizes
the second step. Finally, the predictive accuracy of the classifier is
estimated by the ‘‘Performance’’ operator (Testing). Blocks 4 and 5
in panel A are given to provide ROC curve analysis (e.g. see
Figure S3 for malignant vs benign plus controls and Figure S6 for
controls vs ccRCC).
(TIF)
Figure S3 ROC curve analysis of the model discrimina-
tion performance when applied to an independent
cohort of subjects (malignant vs benign/ctrl). ROC
curves are calculated by first ordering the classified examples by
confidence. Afterwards all the examples are taken into account
with decreasing confidence to plot the false positive rate on the x-
axis and the true positive rate on the y-axis. The threshold (blue
line) refers to the confidence value of the prediction, i.e. if the
confidence of the example to be positive is greater than the
threshold, the example will be classified as positive, if the
confidence is below the threshold, it will be classified as negative.
(TIF)
Figure S4 Box-plot of the eleven ions included in the
model able to distinguish benign or controls from
malignant tumours and statistically different (p,0.05)
in the two groups (see Table 3). Y-axis refers to
arbitrary intensity.
(TIF)
Figure S5 Box-plot of the eight ions included in the
model able to distinguish controls from ccRCC and
statistically different (p,0.05) in the two groups (see
Table 5). Y-axis refers to arbitrary intensity.
(TIF)
Figure S6 ROC curve analysis of the model discrimina-
tion performance when applied to an independent
cohort of subjects (controls vs ccRCC). The threshold (blue
line) refers to the confidence value of the prediction, i.e. if the
confidence of the example to be positive is greater than the
threshold, the example will be classified as positive, if the
confidence is below the threshold, it will be classified as negative.
(TIF)
Table S1 Mean area values of the signals included in
the two clusters discriminating malignant tumours from
benign renal masses plus controls (A) and ccRCC from
controls (B) calculated from raw data before and after
spectra elaboration.
(DOCX)
Materials S1 Details of the experimental protocols.
(DOCX)
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